The effect profile, predicted from an expression map
The receptor populations that produce satiety and the ones that produce nausea overlap substantially. That is why the ceiling of this drug class is where it is, and it is…
Nausea
Page 5 of 5 of this archive, newest first.
The incidence tables, read line by line
Trial adverse-event tables count episodes reported to a study nurse. They are the best data we have and they systematically under-record the mundane.
Reflux, early satiety, and the volume the stomach will accept
A single drug producing both constipation and diarrhoea looks contradictory until the motility data is read properly.
Residual stomach content on endoscopy: the studies
A drug that delays gastric emptying complicates the assumption behind every fasting instruction in perioperative medicine. The professional bodies have moved twice on this…
The incidence tables, read line by line
Trial adverse-event tables count episodes reported to a study nurse. They are the best data we have and they systematically under-record the mundane.
Why your endoscopist wants to know about your injection
This is the single interaction with ordinary medical care that patients most need to disclose, and it is the one most often not asked about.
Background rates, and why they matter for attribution
Rapid weight loss by any means raises gallstone risk. Separating that from a direct drug effect requires a comparator, and the trials have one.
Gallstones during rapid weight loss: drug, or weight loss?
We give background rates alongside trial rates, because an event occurring during treatment is not thereby caused by it.
The interventions with trial support, and the much longer list without
Almost nothing in the standard management repertoire has been tested in a randomised trial in this specific population. We say what is extrapolated and from where.
Severity grading, and the gap between a grade and an experience
Trial adverse-event tables count episodes reported to a study nurse. They are the best data we have and they systematically under-record the mundane.
What the trials counted as intolerance
We set out the questions that distinguish a symptom to manage from a dose to change.
Background rates, and why they matter for attribution
Rapid weight loss by any means raises gallstone risk. Separating that from a direct drug effect requires a comparator, and the trials have one.
Pancreatitis, obstruction, gallbladder: three things nausea can be
Pancreatitis is rare, was adjudicated in the outcome programmes, and did not show the imbalance early case reports suggested.
Attribution is the hard part
We give background rates alongside trial rates, because an event occurring during treatment is not thereby caused by it.
The tolerability data everybody quotes and nobody reads
Almost every figure in circulation about tolerability comes from six publications. This is what they say.